scholarly journals Metronomic treatment of temozolomide increases anti-angiogenicity accompanied by down-regulated O6-methylguanine-DNA methyltransferase expression in endothelial cells

2011 ◽  
Vol 2 (2) ◽  
pp. 343-348 ◽  
Author(s):  
KYUNG-KON KO ◽  
EUN-SANG LEE ◽  
YOUNG AE JOE ◽  
YONG-KIL HONG
Keyword(s):  
Endothelial Cells ◽  
Dna Methyltransferase ◽  
Methylguanine Dna Methyltransferase ◽  
Metronomic Treatment

Posttranslational Regulation of O6-Methylguanine-DNA Methyltransferase (MGMT) and New Opportunities for Treatment of Brain Cancers

2016 ◽  
Vol 16 (6) ◽  
pp. 455-464 ◽  
Author(s):  
Kalkunte S. Srivenugopal ◽  
Amit Rawat ◽  
Suryakant K. Niture ◽  
Ameya Paranjpe ◽  
Chinavenmani Velu ◽  
...  
Keyword(s):  
Dna Methyltransferase ◽  
Posttranslational Regulation ◽  
Methylguanine Dna Methyltransferase

Effect of O6-Substituted Guanine Analogs on O6-methylguanine DNA-methyltransferase Expression and Glioblastoma Cells Viability

2016 ◽  
Vol 13 (1) ◽  
pp. 28-39 ◽  
Author(s):  
Patrick-Denis St-Coeur ◽  
Marc Cormier ◽  
Veronique LeBlanc ◽  
Pier Morin ◽  
Mohamed Touaibia
Keyword(s):  
Dna Methyltransferase ◽  
Glioblastoma Cells ◽  
Methylguanine Dna Methyltransferase

scholarly journals Purification, structure, and biochemical properties of human O6-methylguanine-DNA methyltransferase.

1990 ◽  
Vol 265 (25) ◽  
pp. 14754-14762
Author(s):  
G. Koike ◽  
H. Maki ◽  
H. Takeya ◽  
H. Hayakawa ◽  
M. Sekiguchi
Keyword(s):  
Dna Methyltransferase ◽  
Biochemical Properties ◽  
Methylguanine Dna Methyltransferase

scholarly journals Molecular and Circulating Biomarkers of Brain Tumors

2021 ◽  
Vol 22 (13) ◽  
pp. 7039
Author(s):  
Wojciech Jelski ◽  
Barbara Mroczko
Keyword(s):  
Brain Tumors ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Extracellular Vesicles ◽  
Dna Methyltransferase ◽  
Growth Factor Receptor ◽  
Response To Treatment ◽  
Liquid Biopsies ◽  
Methylguanine Dna Methyltransferase ◽  
The Central Nervous System

Brain tumors are the most common malignant primary intracranial tumors of the central nervous system. They are often recognized too late for successful therapy. Minimally invasive methods are needed to establish a diagnosis or monitor the response to treatment of CNS tumors. Brain tumors release molecular information into the circulation. Liquid biopsies collect and analyze tumor components in body fluids, and there is an increasing interest in the investigation of liquid biopsies as a substitute for tumor tissue. Tumor-derived biomarkers include nucleic acids, proteins, and tumor-derived extracellular vesicles that accumulate in blood or cerebrospinal fluid. In recent years, circulating tumor cells have also been identified in the blood of glioblastoma patients. In this review of the literature, the authors highlight the significance, regulation, and prevalence of molecular biomarkers such as O6-methylguanine-DNA methyltransferase, epidermal growth factor receptor, and isocitrate dehydrogenase. Herein, we critically review the available literature on plasma circulating tumor cells (CTCs), cell-free tumors (ctDNAs), circulating cell-free microRNAs (cfmiRNAs), and circulating extracellular vesicles (EVs) for the diagnosis and monitoring of brain tumor. Currently available markers have significant limitations.While much research has been conductedon these markers, there is still a significant amount that we do not yet understand, which may account for some conflicting reports in the literature.

scholarly journals The Potential Use of Radiomics with Pre-Radiation Therapy MR Imaging in Predicting Risk of Pseudoprogression in Glioblastoma Patients

2021 ◽  
Vol 7 (2) ◽  
pp. 17
Author(s):  
Michael Baine ◽  
Justin Burr ◽  
Qian Du ◽  
Chi Zhang ◽  
Xiaoying Liang ◽  
...  
Keyword(s):  
Clinical Features ◽  
Dna Methyltransferase ◽  
Predictive Ability ◽  
Post Treatment ◽  
Model Combination ◽  
Methylguanine Dna Methyltransferase ◽  
Mri Scans ◽  
Area Under Roc Curve ◽  
True Progression ◽  
Potential Use

Glioblastoma (GBM) is the most common adult glioma. Differentiating post-treatment effects such as pseudoprogression from true progression is paramount for treatment. Radiomics has been shown to predict overall survival and MGMT (methylguanine-DNA methyltransferase) promoter status in those with GBM. A potential application of radiomics is predicting pseudoprogression on pre-radiotherapy (RT) scans for patients with GBM. A retrospective review was performed with radiomic data analyzed using pre-RT MRI scans. Pseudoprogression was defined as post-treatment findings on imaging that resolved with steroids or spontaneously on subsequent imaging. Of the 72 patients identified for the study, 35 were able to be assessed for pseudoprogression, and 8 (22.9%) had pseudoprogression. A total of 841 radiomic features were examined along with clinical features. Receiver operating characteristic (ROC) analyses were performed to determine the AUC (area under ROC curve) of models of clinical features, radiomic features, and combining clinical and radiomic features. Two radiomic features were identified to be the optimal model combination. The ROC analysis found that the predictive ability of this combination was higher than using clinical features alone (mean AUC: 0.82 vs. 0.62). Additionally, combining the radiomic features with clinical factors did not improve predictive ability. Our results indicate that radiomics is potentially capable of predicting future development of pseudoprogression in patients with GBM using pre-RT MRIs.

Sign in / Sign up

Export Citation Format

Share Document